Research programme: antibacterials - 4SC

Drug Profile

Research programme: antibacterials - 4SC

Alternative Names: QSB agents - 4SC; Quorum sensing blocking agents - 4SC

Latest Information Update: 31 Aug 2010

Price : $50

At a glance

  • Originator 4SC
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cystic fibrosis-associated respiratory tract infections; Staphylococcal infections

Most Recent Events

  • 28 May 2005 This programme is still in active development - (BioSquare-2005)
  • 24 Feb 2003 4SC's antibacterials research programme is available for licensing (http://www.4sc.de)
  • 24 Feb 2003 Preclinical trials in Cystic fibrosis-associated respiratory tract infections in Europe (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top